礼来Omvoh(米吉珠单抗)达成临床缓解主要终点,成为首个报告儿童溃疡性结肠炎一年期3期结果的IL-23P19抑制剂
礼来Omvoh(米吉珠单抗)达成临床缓解主要终点,成为首个报告儿童溃疡性结肠炎一年期3期结果的IL-23P19抑制剂
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.